Drug Profile


Alternative Names: Desvenlafaxine hydrochloride; Desvenlafaxine SR; Desvenlafaxine succinate; Desvenlafaxine succinate sustained release; Desvenlafaxine sustained-release; Desvenlaflaxine extended release; DVS-233; DVS-233 SR; DVS-SR; O-desmethylvenlafaxine; Pristiq; WY-45233

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Jiangsu Hansoh Pharmaceutical; Pfizer; Wyeth
  • Class Antidepressants; Cyclohexanols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder; Vasomotor symptoms
  • Discontinued Fibromyalgia; Neuropathic pain

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals
  • 16 Jan 2018 No development reported - Phase-III for Major depressive disorder (In adolescents, In children) in Mexico, Chile, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top